Receptor tyrosine kinase expression of circulating tumor cells in small cell lung cancer

Oncoscience

Volumn 2, Issue 7, 2015, Pages 629-634

  Hamilton, Gerhard ^a   Rath, Barbara ^a   Klameth, Lukas ^a   Hochmair, Maximilian ^b  

^a Ludwig Boltzmann Cluster of Translational Oncology   (Austria)

^b I Interne Lungenabteilung   (Austria)

Author keywords

Cancer stem cells; Circulating tumor cells; Receptor tyrosine kinases; Small cell lung cancer; Wnt Pathway

Indexed keywords

EID: 84958966170     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.179     Document Type: Article

References (47)

1. Siegel RL, Miller KD. Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29.
2. Hensing T, Chawla A, Batra R, Salgia R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014; 799: 85-117.
3. Pietanza MC, Ladanyi M. Bringing the genomic landscape of small-cell lung cancer into focus. Nat Genet. 2012; 44: 1074-1075.
4. Stamatis G. Neuroendocrine tumors of the lung: the role of surgery in small cell lung cancer. Thorac Surg Clin. 2014; 24: 313-326.
5. Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, Passiglia F, Carreca AP, Taverna S, Vento R, Peeters M. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Biophys Acta 2014; 1846: 539-546.
6. Alix-Panabières C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res. 2012; 195: 69-76.
7. Yu N, Zhou J, Cui F, Tang X. Circulating tumor cells in lung cancer: detection methods and clinical applications. Lung 2015; 193: 157-171.
8. Hamilton G, Burghuber O, Zeillinger R. Circulating tumor cells in small cell lung cancer: ex vivo expansion. Lung, in press.
9. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, et al.Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014; 345: 216-220.
10. Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, Schumacher U, Costes V, Maudelonde T, Pantel K, Alix-Panabières C. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015; 75: 892-901.
11. Hamilton G, Rath B, Burghuber O. Chitinase-3-like-1/YKL-40 as marker of circulating cancer cells. Transl Lung Cancer Res. 2015, in press.
12. Hamilton G, Klameth L, Rath B, Thalhammer T. Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. Molecules 2014; 19: 2077-2088.
13. Lazer I. and Lazer I. GelAnalyzer 2010a: Freeware 1D gel electrophoresis image analysis software. 2010, http://www.gelanalyzer.com
14. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117-1134.
15. Zhang H, Photiou A, Grothey A, Stebbing J, Giamas G. The role of pseudokinases in cancer. Cell Signal. 2012; 24: 1173-1184.
16. Wang XC, Katso R, Butler R, Hanby AM, Poulsom R, Jones T, Sheer D, Ganesan TS. H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer. Mol Med. 1996; 2: 189-203.
17. Hovens CM, Stacker SA, Andres AC, Harpur AG, ZiemieckiA, Wilks AF. RYK, a receptor tyrosine kinase-related molecule with unusual kinase domain motifs. Proc Natl Acad Sci. USA 1992; 89: 11818-11822.
18. Halford MM, Stacker SA. Revelations of the RYK receptor. Bioessays 2001; 23: 34-45.
19. Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999; 398: 431-436.
20. Macheda ML, Sun WW, Kugathasan K, Hogan BM, Bower NI, Halford MM, Zhang YF, Jacques BE, Lieschke GJ, Dabdoub A, Stacker SA. The Wnt receptor Ryk plays a role in mammalian planar cell polarity signaling. J Biol Chem. 2012; 287: 29312-29323.
21. Berndt JD, Aoyagi A, Yang P, Anastas JN, Tang L, Moon RT. Mindbomb 1, an E3 ubiquitin ligase, forms a complex with RYK to activate Wnt/ß-catenin signaling. J Cell Biol. 2011; 194: 737-750.
22. Andre P, Wang Q, Wang N, Gao B, Schilit A, Halford MM, Stacker SA, Zhang X, Yang Y. The Wnt coreceptor Ryk regulates Wnt/planar cell polarity by modulating the degradation of the core planar cell polarity component Vangl2. J Biol Chem. 2012; 287: 44518-44525.
23. Halford MM, Armes J, Buchert M, Meskenaite V, Grail D, Hibbs ML, Wilks AF, Farlie PG, Newgreen DF, Hovens CM, Stacker SA. Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk. Nat Genet. 2000; 25: 414-418.
24. Katso RM, Manek S, Ganjavi H, Biddolph S, Charnock MF, Bradburn M, Wells M, Ganesan TS. Overexpression of H-Ryk in epithelial ovarian cancer: prognostic significance of receptor expression. Clin Cancer Res. 2000; 6: 3271-3281.
25. Katso RM, Manek S, Biddolph S, Whittaker R, CharnockMF, Wells M, Ganesan TS. Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. Cancer Res. 1999; 59: 2265-2270.
26. Weiner HL, Rothman M, Miller DC, Ziff EB. Pediatric brain tumors express multiple receptor tyrosine kinases including novel cell adhesion kinases. Pediatr Neurosurg. 1996; 25: 64-71.
27. Li C, Chen H, Hu L, Xing Y, Sasaki T, Villosis MF, Li J, Nishita M, Minami Y, Minoo P. Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol Biol 2008; 9: 11.
28. Debebe Z, Rathmell WK. Ror2 as a Therapeutic Target in Cancer. Pharmacol Ther. 2015; pii: S0163-7258(15)00030-3.
29. Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, Daniels B, Ward RL, Ford CE. Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both ß-catenin dependent and independent Wnt signalling. J Cancer Res Clin Oncol. 2015; 141: 243-254.
30. Morioka K1, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 2009; 100: 1227-1233.
31. Wright TM, Brannon AR, Gordan JD, Mikels AJ, Mitchell C, Chen S, Espinosa I, van de Rijn M, Pruthi R, Wallen E, Edwards L, Nusse R, Rathmell WK. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene 2009; 28: 2513-2523.
32. Maina F. Strategies to overcome drug resistance of receptor tyrosine kinase addicted cancer cells. Curr Med Chem. 2014; 21: 1607-1617.
33. Halford MM, Macheda ML, Parish CL, Takano EA, Fox S, Layton D, Nice E, Stacker SA. A fully human inhibitory monoclonal antibody to the Wnt receptor RYK. PLoS One 2013; 8: e75447.
34. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014; 14: 769-785.
35. Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb Perspect Med. 2012; 2: a006550.
36. Crosier PS, Hall LR, Vitas MR, Lewis PM, Crosier KE Identification of a novel receptor tyrosine kinase expressed in acute myeloid leukemic blasts. Leuk Lymphoma. 1995; 18: 443-449.
37. Boyd AW, Bartlett PF, Lackmann M. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov. 2014; 13: 39-62.
38. Lim JJ, Xie D. The roles and therapeutic potentials of Ephs and ephrins in lung cancer. Exp Cell Res. 2013; 319: 152-159.
39. Brantley-Sieders D, Schmidt S, Parker M, Chen J. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des. 2004; 10: 3431-3442.
40. Day BW, Stringer BW, Boyd AW. Eph receptors as therapeutic targets in glioblastoma. Br J Cancer. 2014; 111: 1255-1261.
41. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015; Apr 7, in press.
42. Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res. 2007; 13: 4042-4045.
43. Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J Natl. Cancer Inst. 2014; 106: djt356.
44. Bafico A, Liu G, Goldin L, Harris V, Aaronson SA. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004; 6: 497-506.
45. Povinelli BJ, Nemeth MJ. Wnt5a regulates hematopoietic stem cell proliferation and repopulation through the Ryk receptor. Stem Cells 2014; 32: 105-115.
46. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 2014; 33: 1316-1324.
47. Mita M, Gordon M, Rosen L, Kapoor N, Choy G, RedkarS, Taverna P, Oganesian A, Sahai A, Azab M, Bristow R, Tolcher AW. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014; 74: 195-204.